Selwan Khamisi

Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Lindholm, Lars; Sjölin, Gabriel; Jonsson, Annika; Abraham‐Nordling, Mirna et al.

Part of Endocrinology, Diabetes & Metabolism, 2025

• DOI for Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Estimation of kidney function in Graves' disease using creatinine and cystatin C

Abbaszadeh, Sorena; Lundqvist, Martin H.; Ljunggren, Östen; Larsson, Anders Olof et al.

Part of Endocrine Connections, 2025

• DOI for Estimation of kidney function in Graves' disease using creatinine and cystatin C
• Download full text (pdf) of Estimation of kidney function in Graves' disease using creatinine and cystatin C

Fracture Incidence in Graves' Disease: A Population-Based Study

Khamisi, Selwan; Udumyan, Ruzan; Sjölin, Gabriel; Calissendorff, Jan et al.

Part of Thyroid, p. 1349-1357, 2023

• DOI for Fracture Incidence in Graves' Disease: A Population-Based Study

Long-Term Outcome of Graves' Disease: A Gender Perspective

Calissendorff, Jan; Cramon, Per Karkov; Hallengren, Bengt; Khamisi, Selwan et al.

Part of Women's Health Reports, p. 487-496, 2023

• DOI for Long-Term Outcome of Graves' Disease: A Gender Perspective
• Download full text (pdf) of Long-Term Outcome of Graves' Disease: A Gender Perspective

Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Khamisi, Selwan; Karlsson, Anders; Ljunggren, Östen; Thulin, Måns et al.

Part of Cytokine, p. 156269, 2023

• DOI for Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
• Download full text (pdf) of Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Lindholm, Lars; Sjölin, Gabriel; Jonsson, Annika; Abraham‐Nordling, Mirna et al.

Part of Endocrinology, Diabetes & Metabolism, 2025

• DOI for Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis

Estimation of kidney function in Graves' disease using creatinine and cystatin C

Abbaszadeh, Sorena; Lundqvist, Martin H.; Ljunggren, Östen; Larsson, Anders Olof et al.

Part of Endocrine Connections, 2025

• DOI for Estimation of kidney function in Graves' disease using creatinine and cystatin C
• Download full text (pdf) of Estimation of kidney function in Graves' disease using creatinine and cystatin C

Fracture Incidence in Graves' Disease: A Population-Based Study

Khamisi, Selwan; Udumyan, Ruzan; Sjölin, Gabriel; Calissendorff, Jan et al.

Part of Thyroid, p. 1349-1357, 2023

• DOI for Fracture Incidence in Graves' Disease: A Population-Based Study

Long-Term Outcome of Graves' Disease: A Gender Perspective

Calissendorff, Jan; Cramon, Per Karkov; Hallengren, Bengt; Khamisi, Selwan et al.

Part of Women's Health Reports, p. 487-496, 2023

• DOI for Long-Term Outcome of Graves' Disease: A Gender Perspective
• Download full text (pdf) of Long-Term Outcome of Graves' Disease: A Gender Perspective

Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Khamisi, Selwan; Karlsson, Anders; Ljunggren, Östen; Thulin, Måns et al.

Part of Cytokine, p. 156269, 2023

• DOI for Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
• Download full text (pdf) of Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in management of Graves' orbitopathy

Khamisi, Selwan; Lundqvist, Martin; Edén Engström, Britt; Larsson, Anders et al.

Part of Experimental and clinical endocrinology & diabetes, p. 236-241, 2023

• DOI for Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in management of Graves' orbitopathy
• Download full text (pdf) of Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in management of Graves' orbitopathy

Vitamin D and bone metabolism in Graves’ disease: a prospective study

Khamisi, Selwan; Lundqvist, Martin H.; Rasmusson, Annica J.; Edén Engström, Britt et al.

Part of Journal of Endocrinological Investigation, p. 425-433, 2023

• DOI for Vitamin D and bone metabolism in Graves’ disease: a prospective study
• Download full text (pdf) of Vitamin D and bone metabolism in Graves’ disease: a prospective study

Long term outcome after toxic nodular goitre

Sjolin, Gabriel; Watt, Torquil; Bystrom, Kristina; Calissendorff, Jan et al.

Part of Thyroid Research, 2022

• DOI for Long term outcome after toxic nodular goitre
• Download full text (pdf) of Long term outcome after toxic nodular goitre

Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'

Sjölin, Gabriel; Byström, Kristina; Holmberg, Mats; Törring, Ove et al.

Part of Endocrinology, Diabetes & Metabolism, 2021

• DOI for Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'
• Download full text (pdf) of Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'

Serum thyroglobulin is associated with orbitopathy in Graves' disease

Khamisi, Selwan; Lundqvist, Martin H.; Emadi, P.; Almby, Kristina E. et al.

Part of Journal of Endocrinological Investigation, p. 1905-1911, 2021

• DOI for Serum thyroglobulin is associated with orbitopathy in Graves' disease
• Download full text (pdf) of Serum thyroglobulin is associated with orbitopathy in Graves' disease

Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey

Törring, Ove; Watt, Torquil; Sjölin, Gabriel; Byström, Kristina et al.

Part of Thyroid, p. 322-331, 2019

• DOI for Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey

The Long-Term Outcome of Treatment for Graves' Hyperthyroidism

Sjölin, Gabriel; Holmberg, Mats; Törring, Ove; Byström, Kristina et al.

Part of Thyroid, p. 1545-1557, 2019

• DOI for The Long-Term Outcome of Treatment for Graves' Hyperthyroidism

A rare case of dyshormonogenetic fetal goiter responding to intra-amniotic thyroxine injections

Khamisi, Selwan; Lindgren, Peter; Karlsson, F Anders

Part of European thyroid journal, p. 51-56, 2014

• DOI for A rare case of dyshormonogenetic fetal goiter responding to intra-amniotic thyroxine injections

Graves' Disease; Aspects on Orbitopathy and Bone Metabolism

Khamisi, Selwan

2023

• Download full text (pdf) of Graves' Disease; Aspects on Orbitopathy and Bone Metabolism